Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to $746000.0.

  • Biofrontera's Change in Accured Expenses fell 2942.29% to $746000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 11522.23%. This contributed to the annual value of -$230000.0 for FY2024, which is 9637.85% up from last year.
  • Per Biofrontera's latest filing, its Change in Accured Expenses stood at $746000.0 for Q3 2025, which was down 2942.29% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Change in Accured Expenses registered a high of $12.4 million during Q3 2021, and its lowest value of -$12.5 million during Q4 2023.
  • In the last 5 years, Biofrontera's Change in Accured Expenses had a median value of $307000.0 in 2025 and averaged $240315.8.
  • Examining YoY changes over the last 5 years, Biofrontera's Change in Accured Expenses showed a top increase of 97040.36% in 2022 and a maximum decrease of 98193.07% in 2022.
  • Quarter analysis of 5 years shows Biofrontera's Change in Accured Expenses stood at $808000.0 in 2021, then plummeted by 981.93% to -$7.1 million in 2022, then tumbled by 75.25% to -$12.5 million in 2023, then soared by 96.84% to -$394000.0 in 2024, then surged by 289.34% to $746000.0 in 2025.
  • Its last three reported values are $746000.0 in Q3 2025, $1.2 million for Q2 2025, and $307000.0 during Q1 2025.